Literature DB >> 17656362

Signaling pathways regulating TC21-induced tumorigenesis.

Mete Erdogan1, Ambra Pozzi, Neil Bhowmick, Harold L Moses, Roy Zent.   

Abstract

TC21(R-Ras2), a Ras-related GTPase with transforming potential similar to H-, K- and N-Ras, is implicated in the pathogenesis of human cancers. Transforming growth factor beta (TGF-beta), a cytokine that plays a significant role in modulating tumorigenesis, normally prevents uncontrolled cell proliferation but paradoxically induces proliferation in H-Ras-transformed cancer cells. Although TC21 activates some pathways that mediate cellular transformation by the classical Ras proteins, the mechanisms through which TC21 induces tumor formation and how TGF-beta regulates TC21 transformed cells is not known. To better understand the role of TC21 in cancer progression, we overexpressed an activated G23V mutant of TC21 in a nontumorigenic murine mammary epithelial (EpH4) cell line. Mutant TC21-expressing cells were significantly more oncogenic than cells expressing activated G12V H-Ras both in vivo and in vitro. TC21-induced transformation and proliferation required activation of p38 MAPK, mTOR (the mammalian target of rapamycin), and phosphoinositide 3-kinase but not Akt/PKB. Transformation by TC21 rendered EpH4 cells insensitive to the growth inhibitory effects of TGF-beta, and the soft agar growth of these cells was increased upon TGF-beta stimulation. Despite losing responsiveness to TGF-beta-mediated growth inhibition, both Smad-dependent and independent pathways remained intact in TC21-transformed cells. Thus, overexpression of active TC21 in EpH4 cells induces tumorigenicity through the phosphoinositide 3-kinase, p38 MAPK, and mTOR pathways, and these cells lose their sensitivity to the normal growth inhibitory role of TGF-beta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17656362     DOI: 10.1074/jbc.M703037200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Activating Mutations of RRAS2 Are a Rare Cause of Noonan Syndrome.

Authors:  Yline Capri; Elisabetta Flex; Oliver H F Krumbach; Giovanna Carpentieri; Serena Cecchetti; Christina Lißewski; Soheila Rezaei Adariani; Denny Schanze; Julia Brinkmann; Juliette Piard; Francesca Pantaleoni; Francesca R Lepri; Elaine Suk-Ying Goh; Karen Chong; Elliot Stieglitz; Julia Meyer; Alma Kuechler; Nuria C Bramswig; Stephanie Sacharow; Marion Strullu; Yoann Vial; Cédric Vignal; George Kensah; Goran Cuturilo; Neda S Kazemein Jasemi; Radovan Dvorsky; Kristin G Monaghan; Lisa M Vincent; Hélène Cavé; Alain Verloes; Mohammad R Ahmadian; Marco Tartaglia; Martin Zenker
Journal:  Am J Hum Genet       Date:  2019-05-23       Impact factor: 11.025

Review 2.  Minireview: physiological and pathological actions of RAS in the ovary.

Authors:  Heng-Yu Fan; Joanne S Richards
Journal:  Mol Endocrinol       Date:  2009-10-30

Review 3.  Concepts and advances in cancer therapeutic vulnerabilities in RAS membrane targeting.

Authors:  James V Michael; Lawrence E Goldfinger
Journal:  Semin Cancer Biol       Date:  2017-12-02       Impact factor: 15.707

4.  Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.

Authors:  S E Wang; Y Yu; T L Criswell; L M Debusk; P C Lin; R Zent; D H Johnson; X Ren; C L Arteaga
Journal:  Oncogene       Date:  2010-04-12       Impact factor: 9.867

5.  In vivo regulation of TGF-β by R-Ras2 revealed through loss of the RasGAP protein NF1.

Authors:  Deanna M Patmore; Sara Welch; Patricia C Fulkerson; Jianqiang Wu; Kwangmin Choi; David Eaves; Jennifer J Kordich; Margaret H Collins; Timothy P Cripe; Nancy Ratner
Journal:  Cancer Res       Date:  2012-08-23       Impact factor: 12.701

6.  siRNA-mediated downregulation of TC21 sensitizes esophageal cancer cells to cisplatin.

Authors:  Raghibul Hasan; Shyam Singh Chauhan; Rinu Sharma; Ranju Ralhan
Journal:  World J Gastroenterol       Date:  2012-08-21       Impact factor: 5.742

7.  Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion.

Authors:  Neetu Dahiya; Kevin G Becker; William H Wood; Yongqing Zhang; Patrice J Morin
Journal:  PLoS One       Date:  2011-07-15       Impact factor: 3.240

8.  RRas2, RhoG and T-cell phagocytosis.

Authors:  Balbino Alarcón; Nuria Martínez-Martín
Journal:  Small GTPases       Date:  2012 Apr-Jun

9.  R-RAS2 overexpression in tumors of the human central nervous system.

Authors:  Sylvia Gutierrez-Erlandsson; Pedro Herrero-Vidal; Marcos Fernandez-Alfara; Susana Hernandez-Garcia; Sandra Gonzalo-Flores; Alberto Mudarra-Rubio; Manuel Fresno; Beatriz Cubelos
Journal:  Mol Cancer       Date:  2013-10-23       Impact factor: 27.401

10.  Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.

Authors:  Matthew T Chang; Saurabh Asthana; Sizhi Paul Gao; Byron H Lee; Jocelyn S Chapman; Cyriac Kandoth; JianJiong Gao; Nicholas D Socci; David B Solit; Adam B Olshen; Nikolaus Schultz; Barry S Taylor
Journal:  Nat Biotechnol       Date:  2015-11-30       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.